ArticleAlzheimer's & dementia (Amsterdam, Netherlands)
Plasma p-tau217, p-tau181, and NfL as early indicators of dementia risk in a community cohort: The Shanghai Aging Study.
Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- From Cerebrospinal Fluid to Blood Draw: Plasma p-Tau217 as a Non-Invasive Biomarker for Alzheimer's Disease: A Fagan Nomogram-Based Meta-Analytic Study.Molecular neurobiology · 2026Pooled it
- Predictive value of plasma p-tau217 for Alzheimer's dementia compared to other blood-based biomarkers.EMBO molecular medicine · 2026Article
- Reliable quantification of renal function from frozen blood samples.medRxiv : the preprint server for health sciences · 2026Article
- Circ_0092222 is Enhanced in Alzheimer's Disease and Exacerbates Aβ-induced Neurotoxicity Through Sponging miR-331-3p.Molecular neurobiology · 2026Article
- Diagnostic and Prognostic Utility of Plasma p-tau217 for Alzheimer's Disease in Chinese Elderly: Insights From the SILCODE Study With a Derived Threshold.European journal of neurology · 2026Article
- Impaired lung function is associated with elevated blood biomarkers of AD/ADRD: unraveling the interplay with risk of dementia.Scientific reports · 2026Article
- Evaluation of plasma p-tau217 biomarkers in detecting amyloid pathology and predicting cognitive outcomes: Observations from Japanese Alzheimer's disease neuroimaging initiative cohort.The journal of prevention of Alzheimer's disease · 2026Article
- The Mitochondrial Guardian α-Amyrin Mitigates Alzheimer's Disease Pathology via Modulation of the DLK-SARM1-ULK1 Axis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Head-to-head comparison of plasma p-tau217 immunoassays for incipient Alzheimer's disease in community cohorts.Alzheimer's research & therapy · 2026Article
- Plasma phosphorylated tau 217 and neurofilament light chain on the association between depressive symptoms and cognitive decline: The Shanghai Aging Study.Psychological medicine · 2026Article
- Clinical translation of fluid, imaging, and digital biomarkers for Alzheimer's disease.Alzheimer's research & therapy · 2026Review
- Impaired lung function is associated with elevated blood biomarkers of AD/ADRD: Unraveling the interplay with risk of dementia.Research square · 2025Article
- Recent molecular insights and biosensor-based diagnostic technologies for hyperphosphorylated Tau in Alzheimer's disease.Alzheimer's research & therapy · 2025Review
- Hearing loss, plasma neurodegenerative biomarkers, and cognitive function: Independent and additive effects.Journal of Alzheimer's disease : JAD · 2025Article
- Head-to-head comparison of plasma p-tau217 immunoassays for incipient Alzheimer's disease in community cohorts.Research square · 2025Article
- Head-to-head comparison of plasma p-tau217 immunoassays for incipient Alzheimer's disease in community cohorts.medRxiv : the preprint server for health sciences · 2025Article
- Impact of COVID-19 pandemic on cognitive decline in community-dwelling older adults in Shanghai: a longitudinal study from 2010 to 2024.The Lancet regional health. Western Pacific · 2025Article
- Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort.Alzheimer's research & therapy · 2025Article
- P-tau217 as a Biomarker in Alzheimer's Disease: Applications in Latin American Populations.International journal of molecular sciences · 2025Review
- Pittsburgh plasma p-tau217: Classification accuracies for autosomal dominant and sporadic Alzheimer's disease in the community.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBlood biomarkers showed values for predicting future cognitive impairment. Evidence from the community-based cohort was limited only in high-income countries.
methodsThis study included 1857 dementia-free community residents recruited in 2009-2011 and followed up in waves 2014-2016 and 2019-2023 in the Shanghai Aging Study. We intended to explore the relationships of baseline plasma ALZpath phosphorylated tau 217 (p-tau217), p-tau181, neurofilament light chain (NfL) with follow-up incident dementia, Alzheimer's disease (AD), and amyloidosis.
resultsHigher concentrations of plasma p-tau217, p-tau181, and NfL were correlated to higher decline speed of Mini-Mental State Examination score, and higher risk of incident dementia and AD. The p-tau217 demonstrated a significant correlation with longitudinal neocortical amyloid-beta (Aβ) deposition ( DISCUSSION: Plasma p-tau217 may be an early predictive marker of AD and Aβ pathology in older community-dwelling individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.